Mesa Labs Inc (MLAB) 112.17 $MLAB
Mesa Labs Acquires Cold Chain Manufacturing Capabilities
GlobeNewswire - Wed Aug 10, 2:00PM CDT
Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company"
today announced the acquisition of certain assets and liabilities of Rapid Aid Corp ("Rapid Aid" by the Company's subsidiary, Mesa Canada, Inc. ("Mesa Canada". Rapid Aid was the Company's exclusive supplier of cold chain packaging gel products ("CC Gels". The acquisition is expected to add approximately 550 basis points to Mesa's Cold Chain Packaging Division gross profit margin and to be neutral to our diluted net income per share ("EPS" during the first 12 months.
MLAB: 112.17 (-1.21)
Allscripts Healthcare (MDRX) Posts In-Line Earnings in Q2
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:50AM CDT
Allscripts Healthcare reported second-quarter 2016 earnings of 10 cents per share, which was in line with the Zacks Consensus Estimate.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), MDRX: 12.88 (-0.03), MLAB: 112.17 (-1.21)
Inogen (INGN) Beats Q2 Earnings & Revenues, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:43PM CDT
Inogen reported second-quarter 2016 earnings of 25 cents per share, which surpassed the Zacks Consensus Estimate by 6 cents.
MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), IDXX: 114.09 (+0.93), MLAB: 112.17 (-1.21)
Mesa Laboratories (MLAB) is Oversold: Can It Recover?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:52AM CDT
Mesa Laboratories Inc. (MLAB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
MLAB: 112.17 (-1.21)
TrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:33AM CDT
TrovaGene Inc (TROV) reported loss of 34 cents per share in the second quarter of 2016, narrower than the year-ago loss of 41 cents.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), TROV: 4.96 (unch), MLAB: 112.17 (-1.21)
Pacific Biosciences (PACB) Q2 Impressive, View Encourages
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 6:45AM CDT
Pacific Biosciences of California Inc. (PACB) reported a loss of 21 cents per share, a penny narrower than the Zacks Consensus Estimate.
BABY: 40.64 (+0.93), PACB: 8.28 (-0.02), MASI: 59.90 (+0.47), MLAB: 112.17 (-1.21)
Mazor Robotics (MZOR) Q2 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:19AM CDT
Mazor Robotics reported adjusted loss of 11 cents in the second quarter of 2016.
MASI: 59.90 (+0.47), MDT: 87.32 (+0.34), MZOR: 22.23 (+0.37), MLAB: 112.17 (-1.21)
Masimo (MASI) Beats Q2 Earnings, Revenues; FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Masimo Corp reported earnings of 49 cents per share that beat the Zacks Consensus Estimate by 8 cents.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), CPHD: 34.42 (+0.16), MLAB: 112.17 (-1.21)
Exactech (EXAC) Beats Earnings on Higher Revenues in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:25AM CDT
Exactech Inc. announced adjusted earnings of 31 cents per share in the second quarter of 2016.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), MLAB: 112.17 (-1.21)
Luminex (LMNX) Gets FDA Nod for Assays; Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:11AM CDT
Luminex reported second-quarter 2016 adjusted earnings of 26 cents per share, which surpassed the Zacks Consensus Estimate of 18 cents.
MASI: 59.90 (+0.47), CPHD: 34.42 (+0.16), LMNX: 21.12 (+0.19), MLAB: 112.17 (-1.21)
CVS Health, Adapt Pharma Team Up to Discount NARCAN Price
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:38PM CDT
CVS Health and Adapt Pharma recently announced a partnership aimed at making the opioid overdose-reversing drug NARCAN Nasal Spray more affordable for patients without insurance coverage.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), CVS: 93.84 (+0.47), MLAB: 112.17 (-1.21)
Cepheid (CPHD) Looks Good: Stock Adds 8% in Session
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:25AM CDT
Cepheid (CPHD) moved big last session, as its shares jumped a little over 8% on the day.
CPHD: 34.42 (+0.16), MLAB: 112.17 (-1.21)
Mesa Labs Reports 16 Percent Increase in First Quarter Revenues
GlobeNewswire - Thu Jul 28, 7:02AM CDT
Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company" today reported a 16 percent increase in revenues for the first quarter ended June 30, 2016.
MLAB: 112.17 (-1.21)
Thermo Fisher Grows Globally; Affimetrix Synergy on Track
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:17AM CDT
On Jun 20, 2016, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
MASI: 59.90 (+0.47), TMO: 151.18 (+0.23), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21)
IRadimed (IRMD) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:18AM CDT
On Jun 17, Zacks Investment Research raised IRadimed Corp. (IRMD) to a Zacks Rank #1 (Strong Buy).
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21)
Can The Uptrend Continue for with Mesa Laboratories (MLAB)?
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:51AM CDT
Investors certainly have to be happy with Mesa Laboratories Inc. (MLAB) and its short term performance
MLAB: 112.17 (-1.21)
Zacks Investment Ideas feature highlights: Apple Hospitality REIT, Coresite Realty, Brookfield CDA, Mesa Labs and Cryolife
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
Zacks Investment Ideas feature highlights: Apple Hospitality REIT, Coresite Realty, Brookfield CDA, Mesa Labs and Cryolife
APLE: 18.74 (-0.20), COR: 79.59 (+0.84), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21), BOXC: 21.80 (+0.17)
CryoLife (CRY) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 6:05AM CDT
On Jun 11, Zacks Investment Research raised CryoLife Inc. (CRY) to a Zacks Rank #1 (Strong Buy).
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21)
Five Recent Strong Buys In Two Industries
Brian Bolan - Zacks Investment Research - Fri Jun 10, 8:32AM CDT
Five Recent Strong Buys In Two Industries
APLE: 18.74 (-0.20), COR: 79.59 (+0.84), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21), BOXC: 21.80 (+0.17)
Mesa Labs Acquires Cold Chain Manufacturing Capabilities
GlobeNewswire - Wed Aug 10, 2:00PM CDT
Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company"
today announced the acquisition of certain assets and liabilities of Rapid Aid Corp ("Rapid Aid" by the Company's subsidiary, Mesa Canada, Inc. ("Mesa Canada". Rapid Aid was the Company's exclusive supplier of cold chain packaging gel products ("CC Gels". The acquisition is expected to add approximately 550 basis points to Mesa's Cold Chain Packaging Division gross profit margin and to be neutral to our diluted net income per share ("EPS" during the first 12 months. MLAB: 112.17 (-1.21)
Allscripts Healthcare (MDRX) Posts In-Line Earnings in Q2
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:50AM CDT
Allscripts Healthcare reported second-quarter 2016 earnings of 10 cents per share, which was in line with the Zacks Consensus Estimate.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), MDRX: 12.88 (-0.03), MLAB: 112.17 (-1.21)
Inogen (INGN) Beats Q2 Earnings & Revenues, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:43PM CDT
Inogen reported second-quarter 2016 earnings of 25 cents per share, which surpassed the Zacks Consensus Estimate by 6 cents.
MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), IDXX: 114.09 (+0.93), MLAB: 112.17 (-1.21)
Mesa Laboratories (MLAB) is Oversold: Can It Recover?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:52AM CDT
Mesa Laboratories Inc. (MLAB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
MLAB: 112.17 (-1.21)
TrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:33AM CDT
TrovaGene Inc (TROV) reported loss of 34 cents per share in the second quarter of 2016, narrower than the year-ago loss of 41 cents.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), TROV: 4.96 (unch), MLAB: 112.17 (-1.21)
Pacific Biosciences (PACB) Q2 Impressive, View Encourages
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 6:45AM CDT
Pacific Biosciences of California Inc. (PACB) reported a loss of 21 cents per share, a penny narrower than the Zacks Consensus Estimate.
BABY: 40.64 (+0.93), PACB: 8.28 (-0.02), MASI: 59.90 (+0.47), MLAB: 112.17 (-1.21)
Mazor Robotics (MZOR) Q2 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:19AM CDT
Mazor Robotics reported adjusted loss of 11 cents in the second quarter of 2016.
MASI: 59.90 (+0.47), MDT: 87.32 (+0.34), MZOR: 22.23 (+0.37), MLAB: 112.17 (-1.21)
Masimo (MASI) Beats Q2 Earnings, Revenues; FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Masimo Corp reported earnings of 49 cents per share that beat the Zacks Consensus Estimate by 8 cents.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), CPHD: 34.42 (+0.16), MLAB: 112.17 (-1.21)
Exactech (EXAC) Beats Earnings on Higher Revenues in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:25AM CDT
Exactech Inc. announced adjusted earnings of 31 cents per share in the second quarter of 2016.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), MLAB: 112.17 (-1.21)
Luminex (LMNX) Gets FDA Nod for Assays; Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:11AM CDT
Luminex reported second-quarter 2016 adjusted earnings of 26 cents per share, which surpassed the Zacks Consensus Estimate of 18 cents.
MASI: 59.90 (+0.47), CPHD: 34.42 (+0.16), LMNX: 21.12 (+0.19), MLAB: 112.17 (-1.21)
CVS Health, Adapt Pharma Team Up to Discount NARCAN Price
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:38PM CDT
CVS Health and Adapt Pharma recently announced a partnership aimed at making the opioid overdose-reversing drug NARCAN Nasal Spray more affordable for patients without insurance coverage.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), CVS: 93.84 (+0.47), MLAB: 112.17 (-1.21)
Cepheid (CPHD) Looks Good: Stock Adds 8% in Session
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:25AM CDT
Cepheid (CPHD) moved big last session, as its shares jumped a little over 8% on the day.
CPHD: 34.42 (+0.16), MLAB: 112.17 (-1.21)
Mesa Labs Reports 16 Percent Increase in First Quarter Revenues
GlobeNewswire - Thu Jul 28, 7:02AM CDT
Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company"
today reported a 16 percent increase in revenues for the first quarter ended June 30, 2016. MLAB: 112.17 (-1.21)
Thermo Fisher Grows Globally; Affimetrix Synergy on Track
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:17AM CDT
On Jun 20, 2016, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
MASI: 59.90 (+0.47), TMO: 151.18 (+0.23), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21)
IRadimed (IRMD) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:18AM CDT
On Jun 17, Zacks Investment Research raised IRadimed Corp. (IRMD) to a Zacks Rank #1 (Strong Buy).
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21)
Can The Uptrend Continue for with Mesa Laboratories (MLAB)?
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:51AM CDT
Investors certainly have to be happy with Mesa Laboratories Inc. (MLAB) and its short term performance
MLAB: 112.17 (-1.21)
Zacks Investment Ideas feature highlights: Apple Hospitality REIT, Coresite Realty, Brookfield CDA, Mesa Labs and Cryolife
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
Zacks Investment Ideas feature highlights: Apple Hospitality REIT, Coresite Realty, Brookfield CDA, Mesa Labs and Cryolife
APLE: 18.74 (-0.20), COR: 79.59 (+0.84), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21), BOXC: 21.80 (+0.17)
CryoLife (CRY) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 6:05AM CDT
On Jun 11, Zacks Investment Research raised CryoLife Inc. (CRY) to a Zacks Rank #1 (Strong Buy).
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21)
Five Recent Strong Buys In Two Industries
Brian Bolan - Zacks Investment Research - Fri Jun 10, 8:32AM CDT
Five Recent Strong Buys In Two Industries
APLE: 18.74 (-0.20), COR: 79.59 (+0.84), CRY: 16.23 (+0.39), MLAB: 112.17 (-1.21), BOXC: 21.80 (+0.17)